This conference is designed for those with a minimum 3 - 5 years industry experience in clinical development research into new anti-cancer agents. Leading experts in the area will provide a comprehensive and in-depth assessment of key new developments in relation to novel approaches to the treatment of cancer, reviewing new anti-cancer agents and cancer therapies, as well as antibody drug conjugates and cancer vaccines. They will also provide an update on the regulatory aspects of cancer drugs, including early access to medicines in clinical development.